Nov 12, 2025 05:00AM Werewolf Therapeutics' (HOWL) an 'Attractive Investment Opportunity'- Citizens

Nov 7, 2025 09:02AM Werewolf Therapeutics presents preclinical data at cancer conference

Oct 8, 2025 08:03AM Werewolf Therapeutics gets FDA fast track status for cancer therapy

Aug 21, 2025 04:03AM Werewolf Therapeutics Inc. (HOWL) PT Lowered to $3 at Citizens JMP

Aug 14, 2025 07:24AM Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 7c

Aug 4, 2025 04:55AM Jefferies Assumes Werewolf Therapeutics Inc. (HOWL) at Buy

May 9, 2025 07:02AM Werewolf Therapeutics Inc. (HOWL) PT Lowered to $10 at H.C. Wainwright

May 8, 2025 04:51PM Werewolf Therapeutics, Inc. (HOWL) Misses Q1 EPS by 2c

May 5, 2025 08:06AM Werewolf Therapeutics (HOWL) Presents New Preclinical Data Further Characterizing WTX-921

Apr 21, 2025 04:29AM Citizens JMP Reiterates Market Outperform Rating on Werewolf Therapeutics Inc. (HOWL)

Mar 11, 2025 04:23PM Werewolf Therapeutics, Inc. (HOWL) Misses Q4 EPS by 4c

Feb 24, 2025 07:31AM Werewolf Therapeutics (HOWL) Appoints Anil Singhal to its Board

Nov 19, 2024 06:59AM H.C. Wainwright Reiterates Buy Rating on Werewolf Therapeutics Inc. (HOWL)

Nov 8, 2024 06:15AM Werewolf Therapeutics, Inc. (HOWL) Tops Q3 EPS by 3c

Nov 7, 2024 09:06AM Werewolf Therapeutics (HOWL) Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Oct 31, 2024 08:02AM Werewolf Therapeutics (HOWL) Announces Promising New Development Candidate, WTX-921

Aug 8, 2024 07:09AM Werewolf Therapeutics, Inc. (HOWL) Misses Q2 EPS by 5c

Jul 2, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on Werewolf Therapeutics Inc. (HOWL)

Jun 26, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on Werewolf Therapeutics Inc. (HOWL)

Jun 26, 2024 05:30AM BofA Securities Reiterates Buy Rating on Werewolf Therapeutics Inc. (HOWL)